SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Sperax is redefining financial autonomy through programmable agents that manage capital, optimize yield, and protect against risk, all transparently on-chain. Founded in 2019, Sperax is backed by leading investors including Jump Trading, Polychain Capital, Amber Group. Sperax offers a new standard in automated, user-driven finance.  The SperaxOS ecosystem is powered by USDs and SPA on Arbitrum, BNB Chain, and other EVM networks. Anchored by two native assets: USDs, a gas-free, auto-yield stablecoin backed by on-chain collateral, and SPA, the governance and value-capture token. Sperax builds open-source tools that turn idle capital into self-optimizing portfolios.  SperaxOS is a cross-chain financial operating system where AI-driven smart agents automate everything from yield farming to payroll, and Demeter, a no-code platform for launching liquidity farms. USDs automatically rebases yield to holders, while SPA lets users register agents, earn protocol fees, and vote on upgrades. Battle-tested through multiple market cycles: Sperax offers individuals, DAOs, and fintechs a borderless toolkit for passive income, risk-managed investing, and fully automated treasury operations, all governed on-chain by its community.

Sperax

Sperax (SPA) is trending due to high anticipation for its SperaxOS launch, which is set to benefit from the recently enacted GENIUS Act by offering a compliant, USD-pegged stablecoin (USDS). This development, coupled with new exchange listings and unusually high trading volume, is fueling community belief in its undervalued status and potential for significant long-term growth.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic (LUNC) is a top trending crypto as its community discusses a potential major comeback, driven by the recent sentencing of Do Kwon, continued token burns, and ongoing development of new ecosystem projects like LUNCVERSE.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

Marathon Digital Holdings is trending as Morgan Stanley's new "Underweight" rating and $8 price target fuel widespread discussion on its performance, particularly given its historical underperformance compared to Bitcoin and other miners. The community is sharply divided, with some anticipating a short squeeze and highlighting its Bitcoin holdings, while others voice strong skepticism over management's value creation and the stalled French acquisition.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is trending as the market's indiscriminate software sector sell-off, fueled by AI disruption fears, has pushed the stock lower despite strong fundamentals and its OpenAI partnership. Community discussion centers on the company's proprietary data moat and consistent earnings beats, with many viewing current prices as a significant buying opportunity ahead of anticipated results.

Helium is a decentralized machine network powered by a physical blockchain. The network is created by gateways who also double as miners on our network. These gateway operators can earn tokens based on coverage they provide as well as transaction fees gained from machines connecting to their gateway  Helium is a new cryptocurrency. Hotspots earn for providing and validating wireless coverage and when devices on the network connect to the internet through Hospots  Helium is mined and distributed to Hotspot Owners, Helium Inc, and investors. There is no pre-mine of Helium, and every month approximately 5,000,000 new Helium are minted.  At the end of each mining period, roughly every 30 to 60 mins, Helium is distributed according to the allocation shown:

Helium

Helium (HNT) is drawing considerable attention following the SEC's dismissal of its lawsuit and a new partnership with AT&T to expand mobile network coverage. This has sparked community discussion about the network's future growth and the recent tokenomics shift consolidating rewards to HNT.

BlackRock Institutional Trust Company N.A. - iShares MSCI India ETF

iShares MSCI India ETF

INDA is trending as the community anticipates a US-India trade deal to resolve tariff disputes, complementing India's strong economic growth and substantial foreign investments in AI and tech manufacturing, which bolster its long-term market appeal.

ProShares Trust - ProShares Ultra Semiconductors 2X Shares

ProShares Ultra Semiconductors

ProShares Ultra Semiconductors ($USD) is trending due to robust growth across the semiconductor sector, fueled by the relentless demand for AI compute, with investors actively discussing its strong leveraged performance driven by key industry players.

Oxford Lane Capital Corp. is a closed-end management investment company, which engages in investing in debt and equity tranches of collateralized loan obligation vehicles. The company was founded on June 9, 2010 and is headquartered in Greenwich, CT.

Oxford Lane Capital Corp

Oxford Lane Capital (OXLC) is trending due to a sharp price decline, significant dividend cut, and recent NAV erosion, leading to widespread investor capitulation and a deep discount to its reported net asset value. While many express severe frustration with management and the CLO sector's performance, some long-term investors are accumulating shares, anticipating a future rebound from new portfolio investments.

Starfighters Space, Inc. is engaged in the research and development of space flight, pilot training, and aeronautics programs. It operates the commercial fleet Lockhead F-104s. The company was founded by Rick Svetkoff on September 6, 2022 and is headquartered in Cape Canaveral, FL.

Starfighters Space Inc

FJET is trending amid intense community debate over its air-launched micro-satellite technology, with bulls anticipating a significant short squeeze fueled by its tiny float and potential FAA Space Launch license approval, while skeptics point to engineering limitations and market viability concerns compared to larger sector players.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending amidst intense buyout speculation, fueled by strategic interest from major pharmaceutical companies and notable institutional share accumulation, which many in the community interpret as a sign of impending acquisition despite persistent frustration over management's prolonged silence on the promising AUR200 pipeline and core drug Lupkynis.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Capricor Therapeutics (NASDAQ:CAPR) Shares Cross Above 50-Day Moving Average - Time to Sell?

Capricor Therapeutics (NASDAQ:CAPR) Stock Passes Above Fifty Day Moving Average - Time to Sell...

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Consensus Rating of "Moderate Buy" from Analysts

Shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the ten ratings firms that are covering the firm, Marketbeat...

Capricor Therapeutics (NASDAQ:CAPR) Stock Price Down 6.7% - Here's Why

Capricor Therapeutics (NASDAQ:CAPR) Trading Down 6.7% - Should You Sell...

CAPR Updates FDA on Deramiocel BLA, Plans HOPE-3 CSR Filing in February

CAPR said the FDA wants the full HOPE-3 study report for Deramiocel and confirmed no new clinical trials are needed.

<ul class="summary-bullets"><li>The U.S. Food and Drug Administration did not request any additional clinical studies or new patient data, as per the company.</li><li>Capricor now plans to submit the data requested by the FDA in February.</li><li>CEO Linda Marbán said that the company is “pleased” that the FDA requested the clinical study report, adding that the request was expected.</li></ul>Shares of Capricor Therapeutics (CAPR) fell 2% on Tuesday morning after the company said that the U.S. Food and Drug Administration (FDA) has requested more data from its trials of Deramiocel.In July, the FDA <a href="https://stocktwits.com/news-articles/markets/equity/capricor-therapeutics-stock-sparks-retail-frenzy-as-traders-hail-best-data-ahead-of-dmd-data-rollout/cLI7F7XRE0P">refused</a> to approve Capricor’s application for Deramiocel for the treatment of Duchenne muscular dystrophy, stating that it does not meet the requirement for substantial evidence of effectiveness, while also expressing the need for additional clinical data. The company said at the time that it intends to meet the FDA’s additional clinical data requirement with a late-stage study and resubmit its application.In December, the company provided the FDA with results from its late-stage HOPE-3 study in which Deramiocel delivered strong signals of benefit for muscle and heart function. However, after reviewing the data, the FDA has formally requested the full HOPE-3 clinical study report (CSR) and supporting data, Capricor said on Tuesday. The agency, however, did not request any additional clinical studies or new patient data, it <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.capricor.com/investors/news-events/press-releases/detail/335/capricor-therapeutics-provides-regulatory-update-on">added.</a><h2 class="st-heading-2">Fresh Timelines</h2>Capricor now plans to submit the new data requested by the FDA in February and expects that the submission will support continued review of its application and address the concerns raised by the FDA in July. &nbsp;CEO of Capricor, Linda Marbán, said that the company is “pleased” that the FDA requested the clinical study report, adding that the request was expected.“Our near-term priority is to address the FDA’s request and continue working collaboratively so that patients with late-stage DMD, who currently have very limited treatment options, may gain access to Deramiocel as soon as possible,” Marbán added.DMD is a genetic disorder characterized by progressive weakness and chronic inflammation of the skeletal, heart, and respiratory muscles. The disease affects approximately 15,000 individuals in the United States and primarily impacts boys.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around CAPR stock stayed within the ‘bearish’ territory while message volume stayed at ‘low’ levels.A Stocktwits user voiced optimism for the drug getting approved in the following three to five months.<stembedurl>https://www.stocktwits.com/jamestrade07/message/642322958</stembedurl>Another user voiced hopes for the stock touching as much as $100 by end of year following Deramiocel approval.<stembedurl>https://www.stocktwits.com/haha1978/message/642314942</stembedurl><a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> has gained 69% over the past 12 months. &nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/moderna-shares-rise-on-five-year-follow-up-takeaways-for-skin-cancer-vaccine/cmUuq4QR4OT">Moderna Shares Rise On Five-Year Follow-Up Takeaways For Skin Cancer Vaccine: Retail Applauds ‘Solid’ Update</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the lCapricor Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

CAPR Stock Slides After FDA Requests More Data For Genetic Disorder Therapy — What Does Retail Think?

The FDA has formally requested the full HOPE-3 clinical study report (CSR) and supporting data, Capricor said on Tuesday. 

Equity

Capricor Therapeutics (NASDAQ:CAPR) Stock Passes Above 50 Day Moving Average - Here's Why

Capricor Therapeutics (NASDAQ:CAPR) Share Price Crosses Above 50-Day Moving Average - Time to Sell...

Capricor Therapeutics (NASDAQ:CAPR) Cut to Sell at Wall Street Zen

Wall Street Zen lowered Capricor Therapeutics from a "hold" rating to a "sell" rating in a report on Sunday...

Capricor Therapeutics (NASDAQ:CAPR) Shares Down 7.8% - What's Next?

Capricor Therapeutics (NASDAQ:CAPR) Stock Price Down 7.8% - Here's Why...

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Average Recommendation of "Moderate Buy" from Analysts

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the ten research firms that are currently covering the firm, MarketBeat...

Capricor Therapeutics (NASDAQ:CAPR) Upgraded at Wall Street Zen

Wall Street Zen raised Capricor Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday...

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

3%+ above current levels

Up 0–3%

Flat to down 3%

Down 3%+

The Nasdaq 100 continues to hinge on mega-cap tech and AI strength. With rate expectations shifting and valuations stretched, even a 3% move could signal a bigger trend. Is momentum building, or fading?

Current Price	$22.45
Prev Close	$23.67
Open	$24.24
Dividend Yield	0.00%
50-Day Moving Average	$25.71
Beta	1.11
Avg. Volume	1.37M
PE Ratio	-12.48

52-Week High	$40.37
52-Week Low	$4.30
Market Capitalization	$1.22B
EPS (Annual)	-$1.15
Price to Book	12.24
Revenue Per Employee	$139,190.41

CAPR
Capricor Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CAPR News

CAPRCapricor Therapeutics Inc